Oppenheimer Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Cuts Target Price to $350
Madrigal Pharmaceuticals (MDGL) Gets a Buy From Oppenheimer
H.C. Wainwright Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $390
Madrigal Pharmaceuticals' Promising Outlook: Buy Rating for Rezdiffra Amidst Enthusiastic Trial Enrollment and Regulatory Milestones
Madrigal Pharmaceuticals Analyst Ratings
Piper Sandler Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $336
Piper Sandler Sticks to Their Buy Rating for Madrigal Pharmaceuticals (MDGL)
JMP Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $415
Buy Rating on Madrigal Pharmaceuticals: Rezdiffra's Rising Prescription Rates and Blockbuster Potential Drive Positive Outlook
Citigroup Maintains Buy on Madrigal Pharmaceuticals, Lowers Price Target to $371
Analysts Offer Insights on Healthcare Companies: Aytu BioScience (AYTU), Madrigal Pharmaceuticals (MDGL) and Third Harmonic Bio, Inc. (THRD)
Buy Rating Affirmed for Madrigal Pharmaceuticals on Strong Rezdiffra Sales and Promising Growth Outlook
Madrigal Pharmaceuticals Analyst Ratings
B. Riley Adjusts Price Target on Madrigal Pharmaceuticals to $194 From $200, Maintains Neutral Rating
Underperform Rating on Madrigal Pharmaceuticals Amid Rezdiffra's Commercial and Competitive Challenges
Leerink Partners Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $390
Buy Rating Affirmed for Madrigal Pharmaceuticals Amid Strong Rezdiffra Launch Prospects
Madrigal Pharmaceuticals Analyst Ratings
JMP Securities Raises Price Target on Madrigal Pharmaceuticals to $385 From $381, Maintains Market Outperform Rating
JMP Securities Maintains Market Outperform on Madrigal Pharmaceuticals, Raises Price Target to $385